Michael Wilcox, MD
Internal Medicine · Walla Walla, WANPI 1881668655
Payments from drug & device makers
Across 225 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$963
- AstraZeneca$632
- Boehringer Ingelheim$578
- Novartis$468
- Bayer$330
- Pfizer$269
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$451%
- Food & beverage$4,82099%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $963 |
| AstraZeneca | 27 | $632 |
| Boehringer Ingelheim | 26 | $578 |
| Novartis | 19 | $468 |
| Bayer | 14 | $330 |
| Pfizer | 21 | $269 |
| GSK | 6 | $221 |
| Abbott | 1 | $157 |
| Exact Sciences | 7 | $154 |
| Sanofi-aventis U.S. LLC | 6 | $154 |
| Phathom Pharmaceuticals, Inc. | 7 | $147 |
| Corcept Therapeutics | 6 | $119 |
| Sanofi Pasteur Inc. | 5 | $84 |
| Merck | 4 | $82 |
| Dexcom, Inc. | 2 | $52 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Lilly USA, LLC | 2 | $38 |
| Mylan Specialty L.p. | 2 | $36 |
| Lundbeck LLC | 1 | $34 |
| Philips North America LLC | 2 | $33 |
| Amgen | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $27 |
| Biogen | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Shionogi Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$157
- BREZTRI$125
- JARDIANCE$124
- BEXSERO$121
How this compares
$4,871 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $134,033 |
| JardianceEmpagliflozin | 120 | $110,122 |
| MounjaroTirzepatide | 57 | $66,078 |
| OzempicSemaglutide | 29 | $40,671 |
| TrulicityDulaglutide | 28 | $32,855 |
| GlyxambiEmpagliflozin/Linagliptin | 47 | $32,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $31,941 |
| XareltoRivaroxaban | 30 | $28,724 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $24,393 |
| FarxigaDapagliflozin Propanediol | 20 | $19,515 |
| LinzessLinaclotide | 22 | $15,474 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $12,661 |
| BelsomraSuvorexant | 20 | $8,905 |
| TradjentaLinagliptin | 13 | $7,645 |
| Ezetimibe | 162 | $6,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $578 | $150,353180 claims |
| PfizerEliquis | $269 | $134,033131 claims |
| Lilly USA, LLCMounjaro, Trulicity | $38 | $98,93385 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $632 | $43,90956 claims |
| Novo NordiskOzempic | $22 | $40,67129 claims |
| GSKTrelegy Ellipta | $221 | $31,94134 claims |
| Johnson & JohnsonXarelto | $19 | $28,72430 claims |
| AbbVieLinzess, Synthroid | $963 | $17,56676 claims |
| MerckBelsomra | $82 | $8,90520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Walla Walla
- Eric BallWalla Walla$183K
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.